Brain cancer breakthrough? old drugs, new hope for glioblastoma
NCT ID NCT07284069
First seen Jan 02, 2026 · Last updated May 24, 2026 · Updated 18 times
Summary
This early-phase trial tests two existing drugs—senicapoc and perampanel—alone and together for newly diagnosed glioblastoma, the most common and aggressive adult brain cancer. The goal is to find safe doses and see if the drugs reach the tumor. About 36 adults will receive the drugs alongside standard care (surgery, radiation, chemo) and be closely monitored for side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aarhus University Hospital, Department of Neurosurgery
RECRUITINGAarhus, Denmark, 8200, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.